For decades, the United States has led the world in drug innovation. We develop medicines to combat cancer, heart disease, AIDS, diabetes and other homicide diseases. A recent study found that there is a “Nature Magazine Index, health science output measured in the US.” Share More multiples are combined than the next 10 major countries. ”

The main reason for US domination in drug development is the world-class research conducted by American bioengineering facilities and the use of tens of millions of people each year to search for treatments. Industry research and development has saved and improved tens of millions of lives in the US alone, perhaps ten times that number worldwide. But somehow, Washington has come to view the industry as a villain.

Mounjaro, the latest US-produced wonder drug, is extremely effective at promoting massive weight loss. Ozempic and Wegovy, manufactured by Danish company Novo Nordisk, are currently used by millions of people. Appetite-control drug users usually lose 10% to 20% of their body fat after taking a shot. This miraculous drug reduces the lives lost from obesity, heart disease, cancer and stress. Meanwhile, millions of Americans are trying to become more active and feel better about themselves.

Many other groundbreaking drugs created by US companies help people live longer and healthier lives. However, the cost of developing new drugs and approving them is usually Beyond According to the Tufts Center for The Drug Development Center, it will take $2 billion – 10-15 years. In addition, the failure rate may be high. 90% of drugs reaching the clinical trial phase are not on the market.

Given these high costs and slow approval times, pharmaceutical companies, researchers, and those who invest billions of dollars of private capital in this study should be convinced that successful drug approval will be rewarded. For all drugs approved by the FDA, there are more than dozens of people who fail and lose money for investors. The rare Wonder Drug “hit” must be rewarded to cover the cost of “misses,” a much more common study of dead ends.

However, the corporate spirit and the future of American drug innovation are threatened by US regulations that allow imitation versions of new drugs to be sold to US consumers.

Today, companies known as “compounds” specialize in creating these imitations and cashing them along the way. They generated nearly $5 billion in revenue in 2023. “There’s a lot of money to make. There’s an endless number of tricks that a comparginer can use.” According to a Robert Caliph, former Commissioner of the Food and Drug Administration.

Compounds free up high R&D costs and late approval times associated with new drug development. Instead, they modify patented FDA-approved medications, adding dosages or tinkering with dosages before modifying mass-produced imitations. However, in the case of weight loss pills, there is no science to support this trick.

Many of these “mimetics” drugs are imported from China. It is imported from China.

Weight loss drugs were so successful that demand exceeded supply. The FDA determined that Ozempic and Wegovy were lacking, and imitation drugs allowed access to the market.

But today there is no shortage. The FDA moved these weight loss medications out of the shortage list, but gave them a pharmacy to formulate Extra 60-90 days To stop their drug production. why? This was a gift that punished businesses for their difficult and expensive jobs of creating and approving these drugs, whilst rewarding millions of dollars (mainly Chinese). The same FDA endlessly delays drug approval, gives counterfeit drugs a free pass.

Mimics can save consumers money in the short term. However, the social costs of the signals this sends to the pharmaceutical industry can be devastating. It will surely cause delays and urgently require medical research in areas such as MS, Alzheimer’s disease, brain tumors, epilepsy and more.

Thomas Phillipson of the University of Chicago has proven that drug price management to keep drug prices low will cut progress on new drugs and kill more people in the long run than price control. Philipson concludes that “compound interest, as is currently being done, violates the exclusiveness granted by the patent, thus reducing the market for new innovation.”

This sounds like when the pound saved by the compound is a future life lost to other fatal illnesses. The FDA should block access to these counterfeit and unsafe medicines and allow the usual patent process to work to protect our intellectual property. Patent protection, which has made America the world’s leading disease fighter, speeds up along with next-generation lifesaving drugs.

Stephen Moore is a senior fellow of the Heritage Foundation and co-founder of Unleash Prosperity. His latest book is “The Miracle of the Trump Economy.”

The opinions and opinions expressed in this commentary are the views of the authors and do not reflect the official position of the Daily Caller News Foundation.

All content created by the Daily Caller News Foundation is an independent, nonpartisan newswire service that is free to use for legitimate news publishers that can provide large audiences. All republished articles must include logos, reporter signatures and DCNF affiliation. For questions regarding our guidelines or partnerships with us, please contact licensing@dailycallernewsfoundation.org.